GlaxoSmithKline Pharmaceuticals Ltd Stock Price Today (NSE: GLAXO)
Fundamental Score
GlaxoSmithKline Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
GlaxoSmithKline Pharmaceuticals Ltd share price today is ₹2603.60, up +0.00% on NSE/BSE as of 17 February 2026. GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹42.32K (Cr). The 52-week high for GLAXO share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 44.39x, GLAXO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 46.87% and a debt-to-equity ratio of 0.02.
GlaxoSmithKline Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
GlaxoSmithKline Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
GlaxoSmithKline Pharmaceuticals Share Price: A ROCE-Focused Analysis
The pharmaceutical industry, characterized by lengthy R&D cycles and stringent regulatory approvals, often sees delayed translation of innovation into immediate profitability. This backdrop informs our analysis of the GlaxoSmithKline Pharmaceuticals share price. Currently trading at ₹2484.0 with a PE ratio of 44.39, GlaxoSmithKline Pharmaceuticals Ltd exhibits a remarkable Return on Capital Employed (ROCE) of 63.25%. This analysis is based on publicly available data and is part of an 80-parameter fundamental audit verified by Sweta Mishra.
The exceptionally high ROCE figure of 63.25% warrants further scrutiny. It suggests that GlaxoSmithKline Pharmaceuticals Ltd is generating significant profits from its invested capital. A high ROCE can be a strong indicator of a company's competitive advantage, often referred to as its economic "moat." In GlaxoSmithKline Pharmaceuticals Ltd's case, this moat could stem from patented drugs, strong brand recognition, or efficient operational management. The ability to consistently generate high returns on capital allows the company to reinvest earnings for future growth, potentially funding further R&D or strategic acquisitions. However, it is important to assess the sustainability of this high ROCE in the face of potential patent expirations and increasing generic competition.
When compared to sector peers, such as
Mankind Pharma Ltd, a deeper analysis of management quality is crucial. While quantitative metrics provide an initial assessment, qualitative factors such as strategic decision-making, risk management, and capital allocation play a vital role in long-term performance. Comparing GlaxoSmithKline Pharmaceuticals Ltd's management effectiveness with that of Mankind Pharma Ltd would require examining factors such as their respective track records in bringing new drugs to market, their ability to navigate regulatory hurdles, and their overall capital allocation strategies. A superior management team, even with a similar ROCE, might suggest a more sustainable competitive advantage.In conclusion, while the high ROCE of GlaxoSmithKline Pharmaceuticals Ltd is an encouraging sign, a comprehensive evaluation should consider the sustainability of this performance, the company's competitive landscape, and the effectiveness of its management team relative to peers. This analysis is purely observational and does not constitute financial advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
GlaxoSmithKline Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLAXO across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (46.87%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (63.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (25.52%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (34.71% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (34.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (811.63x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹5204.49 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 44.39x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (3.06% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
GlaxoSmithKline Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for GlaxoSmithKline Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About GLAXO (GlaxoSmithKline Pharmaceuticals Ltd)
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹42.32K (Cr). GlaxoSmithKline Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 46.87% and a ROCE of 63.25%. The debt-to-equity ratio stands at 0.02, reflecting the company's capital structure. Investors tracking GLAXO share price can monitor key metrics including P/E ratio, promoter holding of 75.00%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
GLAXO Share Price: Frequently Asked Questions
What is the current share price of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO)?
As of 17 Feb 2026, 10:10 am IST, GlaxoSmithKline Pharmaceuticals Ltd share price is ₹2603.60. The GLAXO stock has a market capitalisation of ₹42.32K (Cr) on NSE/BSE.
Is GLAXO share price Overvalued or Undervalued?
GLAXO share price is currently trading at a P/E ratio of 44.39x, compared to the industry average of 31.77x. Based on this relative valuation, the GlaxoSmithKline Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of GLAXO share price?
The 52-week high of GLAXO share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the GlaxoSmithKline Pharmaceuticals Ltd share price?
Key factors influencing GLAXO share price include quarterly earnings growth (Sales Growth: -3.05%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is GlaxoSmithKline Pharmaceuticals Ltd a good stock for long-term investment?
GlaxoSmithKline Pharmaceuticals Ltd shows a 5-year Profit Growth of 34.71% and an ROE of 46.87%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in GLAXO shares.
How does GlaxoSmithKline Pharmaceuticals Ltd compare with its industry peers?
GlaxoSmithKline Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare GLAXO share price P/E of 44.39x and ROE of 46.87% against the industry averages to determine competitive standing.
What is the P/E ratio of GLAXO and what does it mean?
GLAXO share price has a P/E ratio of 44.39x compared to the industry average of 31.77x. Investors pay ₹44 for every ₹1 of annual earnings.
How is GLAXO performing according to Bull Run's analysis?
GLAXO has a Bull Run fundamental score of 58.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GLAXO belong to?
GLAXO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting GlaxoSmithKline Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for GLAXO?
GLAXO has an ROE of 46.87%, which indicates excellent management efficiency. ROE measures how efficiently GlaxoSmithKline Pharmaceuticals Ltd generates profits from shareholders capital.
How is GLAXO debt-to-equity ratio and what does it indicate?
GLAXO has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is GLAXO dividend yield and is it a good dividend stock?
GLAXO offers a dividend yield of 1.68%, meaning you receive ₹1.68 annual dividend for every ₹100 invested in GlaxoSmithKline Pharmaceuticals Ltd shares.
How has GLAXO share price grown over the past 5 years?
GLAXO has achieved 5-year growth rates of: Sales Growth 3.06%, Profit Growth 34.71%, and EPS Growth 34.71%.
What is the promoter holding in GLAXO and why does it matter?
Promoters hold 75.00% of GLAXO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in GlaxoSmithKline Pharmaceuticals Ltd.
What is GLAXO market capitalisation category?
GLAXO has a market capitalisation of ₹42321 crores, placing it in the Large-cap category.
How volatile is GLAXO stock?
GLAXO has a beta of N/A. A beta > 1 suggests the GlaxoSmithKline Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GLAXO operating profit margin trend?
GLAXO has a 5-year average Operating Profit Margin (OPM) of 25.52%, indicating the company's operational efficiency.
How is GLAXO quarterly performance?
Recent quarterly performance shows GlaxoSmithKline Pharmaceuticals Ltd YoY Sales Growth of -3.05% and YoY Profit Growth of 2.57%.
What is the institutional holding pattern in GLAXO?
GLAXO has FII holding of 4.79% and DII holding of 7.75%. Significant institutional holding often suggests professional confidence in the GlaxoSmithKline Pharmaceuticals Ltd stock.